SIETES :: 92915 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Anónimo. Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA eequests withdrawal of weight-loss drug. U.S. Food and Drug Administration 2020:13 de febrero. [Ref.ID 103523]

2.

DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:1 de febrero. [Ref.ID 103519]

3.

McEvoy JB, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:28 de enero. [Ref.ID 103512]

4.

Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 2020:1. [Ref.ID 103506]

5.

Robblee JV, Butterfield RJ, Kang AM, Smith JM. Triptan and ergotamine overdoses in the United States. Analysis of the National Poison Data System. Neurology 2020:1. [Ref.ID 103505]

6.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. . Ann Intern Med 2019;171:248-56. [Ref.ID 103236]

7.

. Roche pays $1.15bn for Sarepta’s Duchenne gene therapy. PMLiVE 2019:23 de diciembre. [Ref.ID 103235]

8.

Taylor P. FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection. PMLiVE 2019:13 de diciembre. [Ref.ID 103233]

9.

Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]

10.

Lutsey PL, Norby FL, Ensrud KE, MacLehose RF, Diem SJ, Chen LY, Alonso A. Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern Med 2019:25 de noviembre. [Ref.ID 103220]

11.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]

12.

Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]

13.

Smith BH, Fletcher EH, Calvin LA. Opioid prescribing is rising in many countries. BMJ 2019;367:17 de octubre. [Ref.ID 103203]

14.

Moncrieff J. Re: Esketamine for treatment resistant depression. Putting drug company interests over the public good. BMJ 2019;366:23 de septiembre. [Ref.ID 103196]

15.

Taylor P. J&J hit by $8bn judgment for man claiming breast growth due to Risperdal. PMLiVE 2019:9 de octubre. [Ref.ID 103192]

16.

Anónimo. Outbreak of lung injury associated with e-cigarette use, or vaping. CDC 2019:3 de octubre. [Ref.ID 103188]

17.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med 2019:30 de julio. [Ref.ID 103183]

18.

Anderson TS, Jing B, Auerbach A, Wray CM, Lee S, Boscardin WJ, Fung K, Ngo S, Silvestrini M, Steinman MA. Clinical outcomes after intensifying antihypertensive medication regimens among older adults at hospital discharge. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103182]

19.

Sainato M. Las farmacéuticas disparan el precio de la insulina y obligan a los estadounidenses a escoger entre techo o medicamentos . eldiario.es 2019:24 de septiembre. [Ref.ID 103180]

20.

Vélez AM. La dueña del monopolio del opio en España oculta los sueldos de su cúpula tras la salida del multimillonario Abelló . eldiario.es 2019:11 de septiembre. [Ref.ID 103173]